Sign in or create an account to add this stock to your watchlist.
About Masimo (NASDAQ:MASI)
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin saturation; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, veterinarians, long term care facilities, and consumers. Masimo Corporation has a strategic partnership with NU Hospitals. The company was founded in 1989 and is headquartered in Irvine, California.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000
Debt
Debt-to-Equity RatioN/A
Current Ratio4.55
Quick Ratio3.86
Price-To-Earnings
Trailing P/E Ratio39.96
Forward P/E Ratio33.99
P/E Growth2.32
Sales & Book Value
Annual Sales$798.11 million
Price / Sales6.35
Cash Flow$3.0670 per share
Price / Cash31.92
Book Value$13.68 per share
Price / Book7.16
Profitability
EPS (Most Recent Fiscal Year)$2.45
Net Income$131.61 million
Net Margins15.99%
Return on Equity23.14%
Return on Assets18.33%
Miscellaneous
Employees1,400
Outstanding Shares51,780,000
Masimo (NASDAQ:MASI) Frequently Asked Questions
What is Masimo's stock symbol?
Masimo trades on the NASDAQ under the ticker symbol "MASI."
How were Masimo's earnings last quarter?
Masimo (NASDAQ:MASI) announced its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.06. The medical equipment provider had revenue of $212.90 million for the quarter, compared to analysts' expectations of $205.65 million. Masimo had a return on equity of 23.14% and a net margin of 15.99%. The business's revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.57 EPS. View Masimo's Earnings History.
When is Masimo's next earnings date?
What guidance has Masimo issued on next quarter's earnings?
Masimo issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.88 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.81.
What price target have analysts set for MASI?
6 analysts have issued twelve-month price targets for Masimo's shares. Their forecasts range from $94.00 to $112.00. On average, they anticipate Masimo's stock price to reach $102.6667 in the next twelve months. View Analyst Ratings for Masimo.
Who are some of Masimo's key competitors?
Some companies that are related to Masimo include Varian Medical Systems (VAR), Sonova (SONVY), LivaNova (LIVN), Getinge Group (GNGBY), CONMED (CNMD), NxStage (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT), Helius Medical Technologies (HSDT), Fonar (FONR) and Second Sight Medical (EYES).
Who are Masimo's key executives?
Masimo's management team includes the folowing people:
- Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 53)
- Mr. Anand Sampath, Chief Operating Officer (Age 52)
- Mr. Yongsam Lee, Exec. VP & Chief Information Officer (Age 53)
- Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 45)
- Dr. Steven J. Barker M.D., Ph.D., Acting Chief Medical Officer and Director (Age 73)
Has Masimo been receiving favorable news coverage?
Headlines about MASI stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo earned a media sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the medical equipment provider an impact score of 46.99 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Masimo's major shareholders?
Masimo's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (14.10%), Point72 Asset Management L.P. (2.67%), Old Mutual Global Investors UK Ltd. (1.82%), Prudential Financial Inc. (1.57%), Northern Trust Corp (1.41%) and Champlain Investment Partners LLC (1.34%). Company insiders that own Masimo stock include Anand Sampath, Joe E Kiani, Jon Coleman, Paul Jansen, Raad Mark De, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee. View Institutional Ownership Trends for Masimo.
Which institutional investors are selling Masimo stock?
MASI stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Russell Investments Group Ltd., American Century Companies Inc., Federated Investors Inc. PA, Allianz Asset Management GmbH, State of Tennessee Treasury Department, Mckinley Capital Management LLC Delaware and California Public Employees Retirement System. Company insiders that have sold Masimo company stock in the last year include Anand Sampath, Jon Coleman, Ramshorst David J Van, Rick Fishel, Sanford Fitch, Steven Barker and Yongsam Lee. View Insider Buying and Selling for Masimo.
Which institutional investors are buying Masimo stock?
MASI stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Champlain Investment Partners LLC, Citigroup Inc., Rockefeller Capital Management L.P., Westfield Capital Management Co. LP, Eagle Asset Management Inc., Massachusetts Financial Services Co. MA and Matarin Capital Management LLC. View Insider Buying and Selling for Masimo.
How do I buy shares of Masimo?
Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Masimo's stock price today?
One share of MASI stock can currently be purchased for approximately $97.90.
How big of a company is Masimo?
Masimo has a market capitalization of $5.03 billion and generates $798.11 million in revenue each year. The medical equipment provider earns $131.61 million in net income (profit) each year or $2.45 on an earnings per share basis. Masimo employs 1,400 workers across the globe.
How can I contact Masimo?
Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]
MarketBeat Community Rating for Masimo (MASI)
MarketBeat's community ratings are surveys of what our community members think about Masimo and other stocks. Vote "Outperform" if you believe MASI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MASI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Masimo (NASDAQ:MASI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for Masimo in the last 12 months. Their average twelve-month price target is $102.6667, suggesting that the stock has a possible upside of 4.87%. The high price target for MASI is $112.00 and the low price target for MASI is $94.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.83 | 2.83 | 2.80 | 2.57 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $102.6667 | $102.1667 | $106.25 | $97.00 |
| Price Target Upside: | 4.87% upside | 18.13% upside | 23.55% upside | 12.79% upside |
Masimo (NASDAQ:MASI) Consensus Price Target History
Masimo (NASDAQ:MASI) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Masimo (NASDAQ:MASI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Masimo (NASDAQ MASI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.60%
Institutional Ownership Percentage: 82.92%
Masimo (NASDAQ MASI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/4/2018 | Ramshorst David J Van | CAO | Sell | 3,000 | $97.50 | $292,500.00 | 2,500 |  |
| 5/3/2018 | Jon Coleman | Insider | Sell | 50,000 | $93.75 | $4,687,500.00 | 34,201 | |
| 5/3/2018 | Sanford Fitch | Director | Sell | 2,000 | $94.00 | $188,000.00 | 62,249 | |
| 4/30/2018 | Sanford Fitch | Director | Sell | 2,000 | $90.37 | $180,740.00 | 64,249 | |
| 4/27/2018 | Yongsam Lee | EVP | Sell | 5,800 | $90.58 | $525,364.00 | 73,975 | |
| 4/24/2018 | Yongsam Lee | EVP | Sell | 4,100 | $90.13 | $369,533.00 | 72,200 | |
| 4/23/2018 | Jon Coleman | Insider | Sell | 24,000 | $90.00 | $2,160,000.00 | 21,201 | |
| 4/2/2018 | Sanford Fitch | Director | Sell | 2,000 | $86.02 | $172,040.00 | 66,249 | |
| 3/29/2018 | Jon Coleman | Insider | Sell | 29,303 | $87.50 | $2,564,012.50 | 20,504 | |
| 3/13/2018 | Yongsam Lee | EVP | Sell | 100 | $90.00 | $9,000.00 | 71,100 | |
| 2/1/2018 | Sanford Fitch | Director | Sell | 2,000 | $93.07 | $186,140.00 | 68,249 | |
| 2/1/2018 | Yongsam Lee | EVP | Sell | 10,000 | $92.95 | $929,500.00 | 79,000 | |
| 1/25/2018 | Sanford Fitch | Director | Sell | 2,000 | $90.00 | $180,000.00 | 70,249 | |
| 1/5/2018 | Yongsam Lee | EVP | Sell | 10,000 | $88.17 | $881,700.00 | 75,018 | |
| 12/4/2017 | Yongsam Lee | EVP | Sell | 18,198 | $88.85 | $1,616,892.30 | 70,800 | |
| 12/1/2017 | Yongsam Lee | EVP | Sell | 5,900 | $88.31 | $521,029.00 | 70,800 | |
| 11/9/2017 | Yongsam Lee | EVP | Sell | 13,976 | $89.43 | $1,249,873.68 | 74,000 | |
| 11/1/2017 | Steven Barker | Director | Sell | 10,000 | $90.00 | $900,000.00 | 73,249 | |
| 11/1/2017 | Yongsam Lee | EVP | Sell | 5,000 | $89.89 | $449,450.00 | 74,000 | |
| 8/17/2017 | Sanford Fitch | Director | Sell | 11,000 | $87.25 | $959,750.00 | 72,249 | |
| 7/20/2017 | Jon Coleman | Insider | Sell | 25,000 | $97.50 | $2,437,500.00 | 32,201 | |
| 7/14/2017 | Rick Fishel | Insider | Sell | 15,000 | $94.85 | $1,422,750.00 | 35,022 | |
| 7/13/2017 | Sanford Fitch | Director | Sell | 6,000 | $91.89 | $551,340.00 | 89,249 | |
| 7/11/2017 | Anand Sampath | COO | Sell | 40,000 | $92.00 | $3,680,000.00 | 20,000 | |
| 7/11/2017 | Rick Fishel | Insider | Sell | 15,000 | $92.85 | $1,392,750.00 | 35,022 | |
| 6/29/2017 | Sanford Fitch | Director | Sell | 14,000 | $92.06 | $1,288,840.00 | 90,249 | |
| 5/1/2017 | Joe E Kiani | CEO | Sell | 145,841 | $102.37 | $14,929,743.17 | 165,082 | |
| 4/28/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 8,000 | $102.75 | $822,000.00 | 2,000 | |
| 4/26/2017 | Joe E Kiani | CEO | Sell | 154,159 | $99.70 | $15,369,652.30 | 219,241 | |
| 4/25/2017 | Joe E Kiani | CEO | Sell | 13,201 | $101.00 | $1,333,301.00 | 219,241 | |
| 4/25/2017 | Jon Coleman | Insider | Sell | 50,000 | $100.00 | $5,000,000.00 | 14,682 | |
| 4/25/2017 | Yongsam Lee | EVP | Sell | 10,000 | $100.00 | $1,000,000.00 | 79,000 | |
| 4/24/2017 | Joe E Kiani | CEO | Sell | 100,000 | $99.00 | $9,900,000.00 | 219,241 | |
| 4/24/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $98.75 | $987,500.00 | 10,000 | |
| 4/20/2017 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $95.75 | $957,500.00 | 4,000 | |
| 4/19/2017 | Yongsam Lee | EVP | Sell | 10,000 | $95.00 | $950,000.00 | 79,000 | |
| 4/4/2017 | Raad Mark De | CFO | Sell | 48,000 | $93.25 | $4,476,000.00 | 14,660 | |
| 3/22/2017 | Sanford Fitch | Director | Sell | 3,000 | $93.23 | $279,690.00 | 80,000 | |
| 3/10/2017 | Paul Jansen | EVP | Sell | 55,611 | $94.47 | $5,253,571.17 | 10,000 | |
| 3/9/2017 | Ramshorst David J Van | Insider | Sell | 7,500 | $94.20 | $706,500.00 | 2,500 | |
| 2/23/2017 | Raad Mark De | CFO | Sell | 30,000 | $86.25 | $2,587,500.00 | 17,660 | |
| 2/17/2017 | Raad Mark De | CFO | Sell | 45,000 | $80.00 | $3,600,000.00 | 17,660 | |
| 2/16/2017 | Joe E Kiani | CEO | Sell | 300,000 | $80.04 | $24,012,000.00 | 119,241 | |
| 2/3/2017 | Jon Coleman | Insider | Sell | 6,000 | $75.00 | $450,000.00 | 13,182 | |
| 2/3/2017 | Raad Mark De | CFO | Sell | 15,000 | $75.00 | $1,125,000.00 | 17,660 | |
| 1/27/2017 | Jon Coleman | Insider | Sell | 5,800 | $72.50 | $420,500.00 | 8,707 | |
| 1/27/2017 | Raad Mark De | CFO | Sell | 15,000 | $72.50 | $1,087,500.00 | 17,660 | |
| 1/20/2017 | Jon Coleman | Insider | Sell | 200 | $72.50 | $14,500.00 | 7,282 | |
| 1/13/2017 | Yongsam Lee | EVP | Sell | 10,000 | $72.00 | $720,000.00 | 79,000 | |
| 1/10/2017 | Jon Coleman | Insider | Sell | 6,000 | $70.00 | $420,000.00 | 13,182 | |
| 1/10/2017 | Raad Mark De | CFO | Sell | 15,000 | $70.00 | $1,050,000.00 | 17,660 | |
| 1/10/2017 | Yongsam Lee | EVP | Sell | 10,000 | $70.00 | $700,000.00 | 79,000 | |
| 1/9/2017 | Paul Jansen | EVP | Sell | 17,945 | $68.88 | $1,236,051.60 | 17,945 | |
| 1/3/2017 | Ramshorst David J Van | Insider | Sell | 4,000 | $67.20 | $268,800.00 | 5,000 | |
| 12/27/2016 | Paul Jansen | EVP | Sell | 2,055 | $68.88 | $141,548.40 | 2,055 | |
| 12/21/2016 | Jon Coleman | Insider | Sell | 4,000 | $67.50 | $270,000.00 | 4,459 | |
| 12/16/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $66.00 | $660,000.00 | 10,000 | |
| 12/8/2016 | Paul Jansen | EVP | Sell | 10,000 | $63.88 | $638,800.00 | 5,000 | |
| 12/7/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 2,293 | $63.00 | $144,459.00 | 4,000 | |
| 12/6/2016 | Joe E Kiani | CEO | Sell | 52,859 | $62.03 | $3,278,843.77 | 119,241 | |
| 12/6/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 4,000 | $63.00 | $252,000.00 | 4,000 | |
| 12/1/2016 | Joe E Kiani | CEO | Sell | 36,119 | $62.06 | $2,241,545.14 | 119,241 | |
| 11/29/2016 | Joe E Kiani | CEO | Sell | 104,870 | $62.27 | $6,530,254.90 | 119,241 | |
| 11/23/2016 | Joe E Kiani | CEO | Sell | 85,771 | $62.06 | $5,322,948.26 | 119,241 | |
| 11/22/2016 | Joe E Kiani | CEO | Sell | 869 | $62.00 | $53,878.00 | 119,241 | |
| 11/21/2016 | Joe E Kiani | CEO | Sell | 30,462 | $62.04 | $1,889,862.48 | 119,241 | |
| 11/18/2016 | Joe E Kiani | CEO | Sell | 20,381 | $62.02 | $1,264,029.62 | 119,241 | |
| 11/1/2016 | Anand Sampath | COO | Sell | 65,000 | $55.04 | $3,577,600.00 | 23,171 | |
| 10/31/2016 | Anand Sampath | COO | Sell | 51,345 | $55.05 | $2,826,542.25 | 23,171 | |
| 10/19/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.05 | $118,100.00 | 46,000 | |
| 10/10/2016 | Joe E Kiani | CEO | Sell | 84,617 | $60.26 | $5,099,020.42 | 126,450 | |
| 10/10/2016 | Yongsam Lee | EVP | Sell | 30,000 | $60.50 | $1,815,000.00 | 93,000 | |
| 10/5/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.58 | $119,160.00 | 48,000 | |
| 10/4/2016 | Joe E Kiani | CEO | Sell | 4,300 | $60.07 | $258,301.00 | 121,441 | |
| 10/3/2016 | Joe E Kiani | CEO | Sell | 2,200 | $60.00 | $132,000.00 | 121,441 | |
| 9/30/2016 | Thomas Samuel Mcclenahan | EVP | Sell | 10,000 | $59.00 | $590,000.00 | 10,000 | |
| 9/27/2016 | Joe E Kiani | CEO | Sell | 4,464 | $60.01 | $267,884.64 | 123,705 | |
| 9/22/2016 | Joe E Kiani | CEO | Sell | 49,484 | $60.18 | $2,977,947.12 | 158,911 | |
| 9/21/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.41 | $118,820.00 | 50,000 | |
| 9/20/2016 | Joe E Kiani | CEO | Sell | 400 | $60.16 | $24,064.00 | 120,240 | |
| 9/19/2016 | Joe E Kiani | CEO | Sell | 999 | $60.03 | $59,969.97 | 120,240 | |
| 9/7/2016 | Joe E Kiani | CEO | Sell | 33,536 | $60.00 | $2,012,160.00 | 152,777 | |
| 9/7/2016 | Jon Coleman | Insider | Sell | 6,000 | $60.00 | $360,000.00 | 759 | |
| 9/7/2016 | Sanford Fitch | Director | Sell | 2,000 | $59.81 | $119,620.00 | | |
| 8/17/2016 | Sanford Fitch | Director | Sell | 2,000 | $58.11 | $116,220.00 | 54,000 | |
| 8/4/2016 | Jon Coleman | Insider | Sell | 22,000 | $56.82 | $1,250,040.00 | 10,459 | |
| 8/4/2016 | Paul Jansen | EVP | Sell | 10,000 | $58.88 | $588,800.00 | 10,000 | |
| 8/3/2016 | Sanford Fitch | Director | Sell | 2,000 | $52.62 | $105,240.00 | 56,000 | |
| 7/20/2016 | Rick Fishel | Insider | Sell | 22,000 | $53.85 | $1,184,700.00 | 42,022 | |
| 7/20/2016 | Sanford Fitch | Director | Sell | 3,000 | $53.48 | $160,440.00 | 58,000 | |
| 6/30/2016 | Ramshorst David J Van | CAO | Sell | 5,000 | $52.50 | $262,500.00 | 3,000 | |
| 6/7/2016 | Joe E Kiani | CEO | Sell | 65,048 | $50.00 | $3,252,400.00 | 175,818 | |
| 6/3/2016 | Joe E Kiani | CEO | Sell | 234,952 | $50.09 | $11,768,745.68 | 313,797 | |
| 6/1/2016 | Jon Coleman | Insider | Sell | 4,000 | $50.00 | $200,000.00 | 4,459 | |
| 5/31/2016 | Raad Mark De | CFO | Sell | 40,000 | $49.43 | $1,977,200.00 | 42,660 | |
| 5/25/2016 | Rick Fishel | Insider | Sell | 25,000 | $49.85 | $1,246,250.00 | 52,022 | |
| 5/5/2016 | Jon Coleman | Insider | Sell | 8,000 | $47.00 | $376,000.00 | 4,459 | |
| 4/28/2016 | Paul Jansen | EVP | Sell | 10,000 | $44.88 | $448,800.00 | 10,000 | |
| 4/27/2016 | Jon Coleman | Insider | Sell | 4,000 | $44.00 | $176,000.00 | 4,459 | |
| 3/23/2016 | Yongsam Lee | EVP | Sell | 96,000 | $39.96 | $3,836,160.00 | 133,000 | |
| 3/22/2016 | Yongsam Lee | EVP | Sell | 32,000 | $40.06 | $1,281,920.00 | 133,000 | |
| 3/21/2016 | Yongsam Lee | EVP | Sell | 32,000 | $39.83 | $1,274,560.00 | 133,000 | |
| 3/15/2016 | Raad Mark De | CFO | Sell | 40,000 | $39.00 | $1,560,000.00 | 42,660 | |
| 2/29/2016 | Raad Mark De | CFO | Sell | 40,000 | $38.11 | $1,524,400.00 | 42,660 | |
| 12/24/2015 | Jon Coleman | insider | Sell | 10,000 | $42.00 | $420,000.00 | 459 | |
| 12/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.00 | $82,000.00 | 61,000 | |
| 11/11/2015 | Sanford Fitch | Director | Sell | 2,000 | $42.67 | $85,340.00 | 61,000 | |
| 11/6/2015 | Anand Sampath | COO | Sell | 45,000 | $42.00 | $1,890,000.00 | | |
| 11/6/2015 | Jon Coleman | insider | Sell | 10,000 | $42.38 | $423,800.00 | 459 | |
| 10/14/2015 | Sanford Fitch | Director | Sell | 2,000 | $39.29 | $78,580.00 | 61,000 | |
| 9/17/2015 | Paul Jansen | EVP | Sell | 10,000 | $42.88 | $428,800.00 | | |
| 9/9/2015 | Sanford Fitch | Director | Sell | 2,000 | $41.29 | $82,580.00 | 61,000 | |
| 8/31/2015 | Thomas Samuel Mcclenahan | EVP | Sell | 22,000 | $40.62 | $893,640.00 | | |
| 8/26/2015 | Paul Jansen | EVP | Sell | 10,000 | $40.88 | $408,800.00 | | |
| 7/22/2015 | Rick Fishel | Insider | Sell | 35,084 | $41.85 | $1,468,265.40 | | |
| 7/21/2015 | Joe E Kiani | CEO | Sell | 300,000 | $40.55 | $12,165,000.00 | | |
| 7/21/2015 | Steven Barker | Director | Sell | 20,000 | $40.00 | $800,000.00 | | |
| 7/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $38.18 | $76,360.00 | | |
| 6/10/2015 | Sanford Fitch | Director | Sell | 2,000 | $36.49 | $72,980.00 | | |
| 6/4/2015 | Steven Barker | Director | Sell | 25,000 | $36.20 | $905,000.00 | | |
| 4/8/2015 | Sanford Fitch | Director | Sell | 2,000 | $34.57 | $69,140.00 | | |
| 2/18/2015 | Rick Fishel | Insider | Sell | 18,170 | $29.85 | $542,374.50 | | |
| 5/22/2013 | Robert Coleman | Director | Sell | 59,400 | $21.93 | $1,302,642.00 | | |
(Data available from 1/1/2013 forward)
Masimo (NASDAQ MASI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Women's Tennis Association to Use Masimo MightySat™ Fingertip Pulse Oximeters to Advance Player Health and ...
www.businesswire.com - May 21 at 10:17 AM |
 | Head to Head Survey: Masimo (MASI) and NxStage (NXTM)
www.americanbankingnews.com - May 20 at 1:19 AM |
| Contrasting Varian Medical Systems (VAR) and Masimo (MASI)
www.americanbankingnews.com - May 16 at 3:16 AM |
| New Study Investigates the Economic Impact and Utility of Continuous Noninvasive Hemoglobin Measurement with ...
www.businesswire.com - May 14 at 11:35 AM |
 | Masimo: Superb Q1, But The Stock Is Too High
seekingalpha.com - May 14 at 11:35 AM |
| BidaskClub Downgrades Masimo (MASI) to Buy
www.americanbankingnews.com - May 14 at 10:46 AM |
| BidaskClub Upgrades Masimo (MASI) to Strong-Buy
www.americanbankingnews.com - May 8 at 3:49 PM |
| Masimo (MASI) Rating Increased to Buy at ValuEngine
www.americanbankingnews.com - May 7 at 10:36 PM |
| Zacks Investment Research Lowers Masimo (MASI) to Hold
www.americanbankingnews.com - May 7 at 2:31 PM |
 | Masimo SET® Pulse Oximetry Helps Form Basis of Utah Senate Resolution on Postoperative Oxygen Saturation Home Monitoring for Patients Prescribed Opioids
finance.yahoo.com - May 7 at 10:32 AM |
| FY2018 EPS Estimates for Masimo (MASI) Raised by Analyst
www.americanbankingnews.com - May 7 at 3:46 AM |
| $208.91 Million in Sales Expected for Masimo (MASI) This Quarter
www.americanbankingnews.com - May 7 at 2:52 AM |
| $0.73 EPS Expected for Masimo (MASI) This Quarter
www.americanbankingnews.com - May 5 at 3:12 PM |
| Insider Selling: Masimo (MASI) CAO Sells 3,000 Shares of Stock
www.americanbankingnews.com - May 4 at 10:15 PM |
| Masimo (MASI) Director Sells $188,000.00 in Stock
www.americanbankingnews.com - May 4 at 7:52 PM |
| Masimo (MASI) Insider Sells $4,687,500.00 in Stock
www.americanbankingnews.com - May 4 at 7:32 PM |
| Masimo (MASI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 4 at 5:46 PM |
| Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
finance.yahoo.com - May 4 at 3:50 PM |
 | Masimo (MASI) Beats on Q1 Earnings, Raises '18 Guidance
www.zacks.com - May 4 at 10:10 AM |
| Q2 2018 EPS Estimates for Masimo Raised by Analyst (MASI)
www.americanbankingnews.com - May 4 at 7:36 AM |
| Masimo (MASI) Earns "Buy" Rating from BTIG Research
www.americanbankingnews.com - May 3 at 6:46 PM |
| Masimo (MASI) and Its Peers Financial Analysis
www.americanbankingnews.com - May 3 at 4:02 PM |
 | BRIEF-Masimo Q1 GAAP Earnings Per Share $0.82
www.reuters.com - May 3 at 10:10 AM |
| Masimo Corporation 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 10:10 AM |
| Masimo: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 10:10 AM |
| Masimo Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 3 at 10:10 AM |
| Masimo Corporation's Strong First Quarter Spurs an Upgrade to Its 2018 Outlook
finance.yahoo.com - May 3 at 10:10 AM |
| Edited Transcript of MASI earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 10:10 AM |
 | Masimo Corporation's Strong First Quarter Spurs an Upgrade to Its 2018 Outlook
www.fool.com - May 3 at 7:18 AM |
| Masimo (MASI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - May 3 at 1:40 AM |
| Masimo (MASI) PT Raised to $94.00
www.americanbankingnews.com - May 2 at 11:06 PM |
| Masimo (MASI) Issues Earnings Results, Beats Expectations By $0.06 EPS
www.americanbankingnews.com - May 2 at 7:32 PM |
| Masimo (MASI) Issues FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 7:30 PM |
| Masimo to Present at Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 2 at 10:14 AM |
| Masimo (MASI) versus Its Rivals Head-To-Head Survey
www.americanbankingnews.com - May 2 at 5:24 AM |
| Head to Head Analysis: Masimo (MASI) & The Competition
www.americanbankingnews.com - May 1 at 9:14 PM |
| Brain Function Monitoring Power Two Investigations into Postoperative Delirium Presented at IARS
www.businesswire.com - May 1 at 3:43 PM |
| Masimo (MASI) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 1 at 12:26 PM |
| Masimo O3® Regional Oximetry and SedLine® Brain Function Monitoring Power Two Investigations into Postoperative Delirium Presented at IARS
finance.yahoo.com - May 1 at 10:18 AM |
| Masimo (MASI) EVP Sells $525,364.00 in Stock
www.americanbankingnews.com - April 30 at 7:46 PM |
| Masimo (MASI) Director Sanford Fitch Sells 2,000 Shares
www.americanbankingnews.com - April 30 at 7:44 PM |
| Does Masimo Corporation’s (NASDAQ:MASI) PE Ratio Signal A Selling Opportunity?
finance.yahoo.com - April 29 at 10:29 AM |
| Financial Comparison: Masimo (MASI) and Its Peers
www.americanbankingnews.com - April 28 at 3:18 PM |
| Head-To-Head Analysis: Masimo (MASI) & Its Peers
www.americanbankingnews.com - April 28 at 3:06 AM |
| Head to Head Review: Masimo (MASI) versus Its Peers
www.americanbankingnews.com - April 27 at 7:04 PM |
| Analyzing Masimo (MASI) and The Competition
www.americanbankingnews.com - April 27 at 5:20 PM |
| Masimo (MASI) EVP Sells $369,533.00 in Stock
www.americanbankingnews.com - April 25 at 10:16 PM |
| Jon Coleman Sells 24,000 Shares of Masimo (MASI) Stock
www.americanbankingnews.com - April 25 at 10:16 PM |
| Masimo (MASI) to Release Earnings on Wednesday
www.americanbankingnews.com - April 25 at 5:46 AM |
| Masimo (MASI) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 25 at 12:26 AM |
Masimo (NASDAQ:MASI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Masimo (NASDAQ:MASI) Income Statement, Balance Sheet and Cash Flow Statement
Masimo (NASDAQ MASI) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
